0001127602-22-017115.txt : 20220609 0001127602-22-017115.hdr.sgml : 20220609 20220609161404 ACCESSION NUMBER: 0001127602-22-017115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220607 FILED AS OF DATE: 20220609 DATE AS OF CHANGE: 20220609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klinger Shannon Thyme CENTRAL INDEX KEY: 0001866132 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 221006117 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE STREET 2: SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-06-07 0001682852 Moderna, Inc. MRNA 0001866132 Klinger Shannon Thyme 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 1 Chief Legal Officer Common Stock 2022-06-07 4 M 0 4554 140.00 A 4554 D Common Stock 2022-06-08 4 S 0 1265 148.1191 D 3289 D Restricted Stock Units 0 2022-06-07 4 M 0 4554 0 D 2022-06-07 Common Stock 4554 13663 D Restricted stock units convert into common stock on a one-for-one basis. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. /s/ Brian Sandstrom, as Attorney-in-Fact 2022-06-09